CHICAGO (GenomeWeb) – Healthcare analytics technology company Cota has entered into a partnership with New York's Memorial Sloan Kettering Cancer Center.
Cota will take anonymized clinical records from MSK and run it through its Cota Nodal Address classification system to build clinical and genomic data sets. This will have the dual purposes of supporting patient care and research at MSK and augmenting Cota's store of evidence.
Cota Nodal Address creates patient cohorts by categorizing patient-specific medical histories, information on their diseases, and planned therapies. "This organized and analyzed data will help our physicians practice more efficiently, optimizing the care a patient receives based on a variety of characteristics and ultimately can improve outcomes for all cancer patients as this knowledge is shared," Paul Sabbatini, MSK's deputy physician-in-chief for clinical research, said in a statement.
MSK and Cota — previously known as Cancer Outcomes Tracking and Analysis — also said that they would form an unspecified technology collaboration centered around analytics for improving disease classification in oncology.
"Cota's powerful technology platform can thread disparate data into a rich longitudinal record to support hypothesis testing, actionable insights, and evidence based decision-making," said Janhvi Patel, Cota's vice president of strategic partnerships. "This collaboration puts Cota at the forefront of precision medicine, creating one of the richest clinical and genomic databases in cancer to fuel innovation in research and development of new therapies and payer-provider value-based programs."